Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Velvet Management
Boston, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Velvet Therapeutics is a private biotechnology company focused on developing innovative therapies for rare diseases and metabolic disorders. Founded by a team of experienced executives from Akcea Therapeutics and Ionis Pharmaceuticals, the company leverages deep expertise in antisense technology and metabolic pathways. Velvet Therapeutics aims to address significant unmet medical needs by targeting specific genetic and molecular drivers of disease. The company's leadership team has a proven track record in drug development and commercialization within the rare disease space.
- Therapeutic areas
- Rare DiseasesGastroenterologyMetabolic Disorders
- Modalities
- Small moleculeAntisense oligonucleotide
- Industry
- Biotech
Beyond the preview
Go deeper on Velvet Management.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Velvet Management.